Business
PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine
BOSTON, April 02, 2026--PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine
About this update from Puretech Health Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":7367,"height":2362,"url":"https://media.zenfs.com/en/business-wire.com/3cfdd1d70f8a5084ecefeefce20981e1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/co0q3gGELox.duZIQ8XPHQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwOA--/https://media.zenfs.com/en/business-wire.com/3cfdd1d70f8a5084ecefeefce20981e1","width":960,"height":308},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/qtIsEOJAb4SUpXtMgrxMBQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzA-/https://media.zenfs.com/en/business-wire.com/3cfdd1d70f8a5084ecefeefce20981e1","width":1200,"height":385}},"lazy":false},{"type":"text","content":"Deupirfenidone 825 mg TID monotherapy significantly slowed lung function decline versus placebo at 26 weeks in people with idiopathic pulmonary fibrosis (adjusted mean FVC difference 91 mL; p=0.02), approaching the lung function change expected in normal, healthy aging","length":269,"tagName":"p","attribs":{}},{"type":"text","content":"First industry-sponsored IPF trial to include a current standard-of-care treatment as an active comparator in addition to a placebo arm, strengthening interpretation of efficacy and safety findings","length":197,"tagName":"p","attribs":{}},{"type":"text","content":"PureTech's Founded Entity, Celea Therapeutics, is working to complete a financing to enable the initiation of the Phase 3 SURPASS-IPF trial in the first half of 2026","length":169,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON, April 02, 2026--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced the publication of results from the Phase 2b ELEVATE IPF trial of deupirfenidone for the potential treatment of idiopathic pulmonary fibrosis (IPF) in The American Journal of Respiratory and Critical Care Medicine (AJRCCM). The results from this trial informed the design of the upcoming Phase 3 SURPASS-IPF trial, which will evaluate deupirfenidone 825 mg three times a day (TID) monotherapy as compared to pirfenidone 801 mg TID monotherapy, in a head-to-head study powered to test for superiority. PureTech’s Founded Entity, Celea...